Kyntra Bio, Inc.
KYNBHealthcare|Biotechnology|US
$3.73
+0.07 (+1.91%)
DCF Value
$12.09
Cash / Share
$22.56
Clinical Trials (62)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05011188 FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer | Metastatic Castration-resistant Prostate Cancer, Prostate Cancer | P1P2 | Active | 44 | Open-label | FOR46, Enzalutamide, Pegfilgrastim |
| NCT06842498 A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Metastatic Castration-Resistant Prostate Cancer | P2 | Recruiting | 75 | RCT, Open-label | FG-3246 |
| NCT07664397 Imaging Study of [89Zr]DFO-YS5 for Cancer Detection | Bladder Cancer, Nerve Sheath Tumor | P1 | Recruiting | 40 | Open-label | [89Zr]DFO-YS5 |
| NCT04059913 Evaluate the Efficacy and Safety of Multiple Roxadustat Dosing Regimens for the Treatment of Anemia in Dialysis Participants With Chronic Kidney Disease | CKD Anemia in Dialysis Participants | P4 | Completed | 318 | RCT, Open-label | Roxadustat |
| NCT02952092 A Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia | Hemodialysis Chronic Kidney Disease Patients With Anemia | P3 | Completed | 303 | RCT, Double-blind | roxadustat, Darbepoetin alfa |
| NCT02278341 Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis | Anemia, End Stage Renal Disease (ESRD) | P3 | Completed | 838 | RCT, Open-label | Roxadustat, Epoetin alfa, Darbepoetin alfa, Iron |
| NCT03263091 Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden | Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts), Anemia | P3 | Terminated | 184 | RCT, Double-blind | Roxadustat, Placebo |
| NCT02021318 Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa | Anemia in Chronic Kidney Disease in Non-dialysis Patients | P3 | Completed | 616 | RCT, Open-label | Roxadustat, Darbepoetin alfa |
| NCT02988973 A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With Anemia | Chronic Kidney Disease | P3 | Completed | 334 | RCT, Open-label | roxadustat, DA |
| NCT02779764 A Long Term Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia Converted From Erythropoieses Stimulating Agent (ESA) Treatment | Hemodialysis Patients With Renal Anemia | P3 | Completed | 164 | Open-label | roxadustat |
| NCT02780726 A Study of Intermittent Oral Dosing of ASP1517 in Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia | Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia | P3 | Completed | 56 | RCT, Open-label | roxadustat |
| NCT01887600 Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis | Anemia in Chronic Kidney Disease in Non-dialysis Patients | P3 | Completed | 594 | RCT, Double-blind | Roxadustat, Placebo |
| NCT02780141 A Study of Intermittent Oral Dosing of ASP1517 in Erythropoieses Stimulating Agent (ESA)-Naive Hemodialysis Chronic Kidney Disease Patients With Anemia | ESA-naive Hemodialysis Chronic Kidney Disease Patients With Anemia | P3 | Completed | 75 | RCT, Open-label | roxadustat |
| NCT02964936 A Study of Intermittent Oral Dosing of ASP1517 in ESA-untreated Chronic Kidney Disease Patients With Anemia | Chronic Kidney Disease | P3 | Completed | 100 | RCT, Open-label | roxadustat |
| NCT03303066 Efficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome (MDS) | Anemia, Myelodysplastic Syndrome | P2P3 | Completed | 43 | RCT, Double-blind | FG-4592, Placebo |
| NCT02174627 Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis | Anemia | P3 | Completed | 2,781 | RCT, Double-blind | Roxadustat, Placebo |
| NCT03941093 Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer | Pancreatic Cancer Non-resectable | P3 | Completed | 284 | RCT, Double-blind | Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX, Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX |
| NCT07722988 A Study to Investigate the Efficacy and Safety of Roxadustat (FG-4592) for Treating Anemia in Participants With Myelodysplastic Syndromes (MDS) | Myelodysplastic Syndromes | P3 | Not Yet Recruiting | 201 | RCT, Double-blind | Roxadustat, Placebo |
| NCT03955146 Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis | P3 | Terminated | 393 | RCT, Double-blind | Pamrevlumab, Placebo |
| NCT01750190 A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving Dialysis | CKD Anemia | P3 | Completed | 922 | RCT, Double-blind | Roxadustat, Placebo |
| NCT04371666 Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambulatory Duchenne Muscular Dystrophy (DMD) | Duchenne Muscular Dystrophy | P3 | Terminated | 98 | RCT, Double-blind | Pamrevlumab, Placebo, Corticosteroids |
| NCT04410198 Study of Roxadustat Conversion in Participants Receiving Stable Erythropoiesis-Stimulating Agent (ESA) or as Initial Anemia Treatment in Chronic Dialysis Participants | Anemia Associated With End Stage Renal Disease (ESRD) | P3 | Completed | 203 | Open-label | Roxadustat |
| NCT04419558 Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis | P3 | Terminated | 372 | RCT, Double-blind | Pamrevlumab, Placebo |
| NCT04484857 Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants | Anemia Associated With End Stage Renal Disease | P3 | Completed | 283 | Open-label | Roxadustat |
| NCT02652819 FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease Not on Dialysis | Anemia | P3 | Completed | 154 | RCT, Double-blind | FG-4592, Placebo |
| NCT02273726 Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis | CKD Anemia in Stable Dialysis Patients | P3 | Completed | 741 | RCT, Open-label | Epoetin Alfa, Roxadustat |
| NCT02174731 Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis. | Anemia | P3 | Completed | 2,133 | RCT, Open-label | Roxadustat, Epoetin alfa |
| NCT04632940 Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMD | Duchenne Muscular Dystrophy | P3 | Terminated | 73 | RCT, Double-blind | Pamrevlumab, Placebo, Corticosteroids |
| NCT05301517 A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies | Chemotherapy Induced Anemia | P3 | Completed | 159 | RCT, Open-label | SEPO®, Roxadustat |
| NCT02052310 Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants | Anemia in Incident Dialysis Patients | P3 | Completed | 1,043 | RCT, Open-label | Roxadustat, Epoetin Alfa |
| NCT04621331 Investigating the Efficacy, Safety and PK of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With CKD | Anemia Associated With Chronic Kidney Disease | P3 | Withdrawn | — | Open-label | Roxadustat |
| NCT02652806 FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease | Anemia | P3 | Completed | 305 | RCT, Open-label | FG-4592, Epoetin Alfa |
| NCT01244763 Study of Roxadustat in Non-Dialysis Chronic Kidney Disease Participants With Anemia | Chronic Kidney Disease, Anemia | P2 | Completed | 145 | RCT, Open-label | Roxadustat |
| NCT04076943 Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced Anemia | Chemotherapy Induced Anemia | P2 | Completed | 92 | Open-label | Roxadustat |
| NCT01630889 Open-Label Extension Study for the Long-Term Efficacy and Safety of Roxadustat in Participants With Dialysis and Non-Dialysis Chronic Kidney Disease | Chronic Kidney Disease, End Stage Renal Disease | P2 | Completed | 15 | Open-label | Roxadustat |
| NCT01147666 Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis | End Stage Renal Disease, Anemia | P2 | Completed | 161 | RCT, Double-blind | Roxadustat, Epoetin Alfa |
| NCT00761657 Phase 2 Study of Roxadustat in Participants With Anemia and Chronic Kidney Disease Not Requiring Dialysis | Chronic Kidney Disease, Anemia | P2 | Completed | 117 | RCT, Single-blind | Roxadustat, Placebo |
| NCT01414075 Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment | Dialysis, Anemia | P2 | Completed | 60 | RCT, Open-label | Roxadustat, Oral Iron, IV Iron |
| NCT00456053 A Randomized Study of the Safety and Efficacy of FG-2216 in Subjects With Renal Anemia Not Requiring Dialysis and Not Receiving Recombinant Human Erythropoietin | Renal Anemia | P2 | Completed | 145 | RCT, Single-blind | FG2216 |
| NCT01890265 Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis | P2 | Completed | 160 | RCT, Double-blind | Pamrevlumab, Placebo, Sub-Study: Pirfenidone, Sub-Study: Nintedanib |
| NCT01596855 Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis in China | Anemia in End Stage Renal Disease | P2 | Completed | 96 | RCT, Open-label | FG-4592, Epoetin Alfa |
| NCT02210559 A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer | Pancreatic Cancer (Unresectable) | P1P2 | Completed | 37 | RCT, Open-label | FG-3019, Gemcitabine, Nab-paclitaxel |
| NCT01217632 A Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B Infection | Liver Fibrosis Due to Chronic Hepatitis B Infection | P2 | Terminated | 114 | RCT, Double-blind | FG-3019, Placebo, Entecavir |
| NCT00913393 Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy | Type 2 Diabetes Mellitus, Diabetic Nephropathy | P2 | Terminated | 46 | RCT, Double-blind | FG-3019, FG-3019, Placebo |
| NCT01262001 Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | P2 | Completed | 90 | Open-label | FG-3019, FG-3019 |
| NCT04432298 Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Participants With Acute COVID-19 Disease | COVID-19 | P2 | Terminated | 22 | RCT, Double-blind | Pamrevlumab, Placebo |
| NCT01599507 Study of FG-4592 in Subjects With Chronic Kidney Disease in China | Anemia in Chronic Kidney Disease | P2 | Completed | 91 | RCT, Double-blind | FG-4592, Placebo |
| NCT02606136 Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) | Duchenne Muscular Dystrophy | P2 | Terminated | 21 | Open-label | Pamrevlumab |
| NCT02965040 A Phase 1 Study of Roxadustat in Subjects With Different Degrees of Renal Function | Normal Renal Function, Impaired Renal Function | P1 | Completed | 34 | Open-label | Roxadustat |
| NCT02693613 Pharmacokinetic Study of ASP1517 With Kremezin® | Healthy Volunteers | P1 | Completed | 34 | RCT, Open-label | ASP1517, Kremezin® |
| NCT02161796 A Study to Evaluate the Dose-proportionality and Effects of FG-4592 in Healthy Young and Elderly Male and Female Subjects | PK for FG-4592, Healthy Subjects | P1 | Completed | 48 | RCT, Double-blind | FG-4592, Placebo |
| NCT02952040 A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP1517 and Lanthanum Carbonate Hydrate | Healthy Subjects | P1 | Completed | 18 | RCT, Open-label | ASP1517, Lanthanum carbonate hydrate |
| NCT02252731 A Study to Evaluate the Effects of Multiple Doses of FG-4592 on the Exposure, Safety and Tolerability and Effect of Warfarin in Healthy Subjects | Pharmacokinetics of FG-4592, Healthy Subjects | P1 | Completed | 22 | Open-label | Warfarin, FG-4592 |
| NCT03960489 A Study to Assess the Relative Bioavailability of Roxadustat Following a Single Dose of Pediatric Azo Dye-free Tablet Formulation and Pediatric Azo Dye-free Mini-tablet Formulation Compared to a Single Dose of Azo Dye-containing Tablet Formulation in Healthy Adult Subjects | Healthy Adult Subjects | P1 | Completed | 24 | RCT, Open-label | Roxadustat |
| NCT02161224 A Study to Investigate the Exposure and Safety and Tolerability of a Single Dose of FG-4592 in Subjects With Moderately Diminished Liver Function Compared to Those With Normal Liver Function | PK of FG-4592, Hepatic Insufficiency | P1 | Completed | 16 | Open-label | FG-4592 |
| NCT02805374 A Food Effect Study to Evaluate the Pharmacokinetics of ASP1517 | Healthy Subjects | P1 | Completed | 16 | RCT, Open-label | ASP1517 |
| NCT00754143 Phase 1 Study of FG-3019 in Subjects With Type 1 or Type 2 Diabetes Mellitus and Diabetic Nephropathy | Diabetes Mellitus, Diabetic Nephropathy | P1 | Completed | 38 | RCT, Double-blind | FG-3019, FG-3019, FG-3019 |
| NCT01376063 Study to Investigate the Interaction Between FG-4592 and Rosiglitazone in Healthy Adult Subjects | Healthy Adult Subjects | P1 | Completed | 20 | Open-label | FG-4592 |
| NCT00102297 Study of the Safety of FG-3019 in Incipient Nephropathy Due to Type 1 or Type 2 Diabetes Mellitus | Diabetes Mellitus | P1 | Completed | 20 | Open-label | FG-3019 |
| NCT00074698 Safety and Tolerability Study of FG-3019 in Participants With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | P1 | Completed | 21 | RCT, Open-label | FG-3019 |
| NCT00782561 Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS) | Focal Segmental Glomerulosclerosis | P1 | Terminated | 2 | Open-label | FG-3019 |
| NCT01181245 A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer | Locally Advanced or Metastatic Pancreatic Cancer | P1 | Completed | 50 | Open-label | FG-3019 |